Suresnes, France

Pascal Brandys

This inventor holds 1 USPTO granted patent. Top assignee: Genset. Active years: 2002.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 117(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Pascal Brandys

Introduction

Pascal Brandys is a notable inventor based in Suresnes, France. He has made significant contributions to the field of biotechnology, particularly in the development of oligonucleotides. His work has implications for various applications in genetic research and therapeutic interventions.

Latest Patents

One of Pascal Brandys' key patents is titled "Closed antisense and sense oligonucleotides and their applications." This patent describes an antisense or sense agent of the oligonucleotide type, which includes a single-stranded oligonucleotide sequence. This sequence has a binding affinity for DNA, RNA, or protein, and features unique structural characteristics that enhance its functionality. He holds 1 patent in this area.

Career Highlights

Pascal Brandys has been associated with Genset, a company known for its innovative approaches in genetic research. His work at Genset has allowed him to explore the potential of oligonucleotides in various scientific applications. His contributions have been instrumental in advancing the understanding of genetic materials.

Collaborations

Throughout his career, Pascal has collaborated with several talented individuals, including Marta Blumenfeld and Marc Vasseur. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Pascal Brandys is a distinguished inventor whose work in oligonucleotides has paved the way for advancements in biotechnology. His patent and collaborations reflect his commitment to innovation in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…